We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
-7.78%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$1.62B
AUM Growth
-$116M
(-6.7%)
Cap. Flow
+$444M
Cap. Flow
% of AUM
27.45%
Top 10 Holdings %
Top 10 Hldgs %
37.93%
Holding
108
New
37
Increased
28
Reduced
11
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Burlington
BURL
|
+$54.3M |
| 2 |
Energizer
ENR
|
+$39.6M |
| 3 |
Amazon
AMZN
|
+$36.8M |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$35.3M |
| 5 |
Avalo Therapeutics
AVTX
|
+$27.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Williams-Sonoma
WSM
|
+$32.8M |
| 2 |
AutoZone
AZO
|
+$29.4M |
| 3 |
Envista
NVST
|
+$25.1M |
| 4 |
Biogen
BIIB
|
+$21.2M |
| 5 |
Estee Lauder
EL
|
+$20.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.87% |
| 2 | Consumer Staples | 13.75% |
| 3 | Consumer Discretionary | 13.46% |
| 4 | Technology | 4.19% |
| 5 | Industrials | 2.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
| $155M | 9.56% |
6,000
| – | – |
|
2
PUT
iShares Russell 2000 ETF
IWM
$80.9B
| $80.1M | 4.95% |
7,000
-7,000
| -50% | -$1.04M |
|
|
3
Avalo Therapeutics
AVTX
$976M
| $69.8M | 4.32% |
9,778
+2,596
| +36% | +$27.5M |
|
4
Supernus Pharmaceuticals
SUPN
$2.68B
| $54M | 3.34% |
3,000,000
+1,288,000
| +75% | +$27.1M |
|
5
Vanda Pharmaceuticals
VNDA
$312M
| $47.3M | 2.93% |
4,568,000
+1,740,000
| +62% | +$21.6M |
|
|
6
Amazon
AMZN
$2.5T
| $44.8M | 2.77% |
460,000
+380,000
| +475% | +$36.8M |
|
|
VXRT
7
DELISTED
Vaxart
VXRT
| $44.6M | 2.76% |
25,200,000
| – | – |
|
|
8
Burlington
BURL
$22B
| $40.9M | 2.53% |
+258,004
| New | +$54.3M |
|
9
Incyte
INCY
$23.5B
| $38.7M | 2.39% |
528,000
+253,000
| +92% | +$19.1M |
|
|
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
| $38.4M | 2.38% |
428,000
+360,000
| +529% | +$35.3M |
|
11
Central Garden & Pet Co Class A
CENTA
$2.41B
| $38.4M | 2.37% |
1,875,000
+777,500
| +71% | +$17.3M |
|
12
Bristol-Myers Squibb
BMY
$127B
| $36.1M | 2.23% |
648,000
+148,000
| +30% | +$9.05M |
|
|
BHVN
13
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $35.9M | 2.22% |
1,056,000
+444,000
| +73% | +$20.3M |
|
14
Regeneron Pharmaceuticals
REGN
$68.8B
| $31.3M | 1.93% |
64,000
-36,000
| -36% | -$14.8M |
|
15
Dropbox
DBX
$6.81B
| $30.6M | 1.89% |
1,692,000
+234,000
| +16% | +$4.26M |
|
16
Deckers Outdoor
DECK
$13.3B
| $30.5M | 1.89% |
1,365,108
+260,508
| +24% | +$7.25M |
|
|
BLUE
17
DELISTED
bluebird bio
BLUE
| $29.8M | 1.84% |
50,026
+24,087
| +93% | +$23.5M |
|
18
Kraft Heinz
KHC
$30.4B
| $29.7M | 1.84% |
1,200,000
+510,000
| +74% | +$14M |
|
19
Enanta Pharmaceuticals
ENTA
$372M
| $29.2M | 1.81% |
568,000
+174,105
| +44% | +$9.28M |
|
20
PTC Therapeutics
PTCT
$6.37B
| $26.8M | 1.66% |
600,000
-158,000
| -21% | -$7.96M |
|
|
21
Energizer
ENR
$1.44B
| $26.4M | 1.63% |
+872,000
| New | +$39.6M |
|
|
AMAG
22
DELISTED
AMAG Pharmaceuticals
AMAG
| $25.5M | 1.57% |
4,120,000
+60,000
| +1% | +$529K |
|
23
Dollar General
DG
$25.9B
| $25M | 1.55% |
+165,633
| New | +$25.6M |
|
|
MRTX
24
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $24M | 1.48% |
312,000
+192,000
| +160% | +$17.2M |
|
25
Five Below
FIVE
$11.2B
| $23.5M | 1.46% |
334,594
+244,137
| +270% | +$24.8M |
|
Similar funds
CRC
RMDI
F
DWM
DCP
EW
AIM
O
Armistice Capital's Q1 2020 Portfolio in Review
As of Q1 2020, Armistice Capital held 108 positions worth $1.62B, down 6.7% from $1.73B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Armistice Capital deployed $444M of net new capital in Q1 2020, opening 37 new positions and adding to 28 existing holdings. Its largest new stake was Burlington: 258,004 shares worth $40.9M.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 42% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Biogen, an estimated $21.2M trimmed.
- Armistice Capital's largest Q1 2020 buy was Burlington: 258,004 shares worth $40.9M.
- Armistice Capital added most to Amazon in Q1 2020, an estimated $36.8M increase.
- Armistice Capital's biggest Q1 2020 reduction was Biogen, cutting an estimated $21.2M.
- Armistice Capital fully exited Williams-Sonoma in Q1 2020, selling an estimated $32.8M.
- Armistice Capital's ten largest holdings make up 38% of its $1.62B portfolio in Q1 2020.
- Armistice Capital opened 37 new positions and closed 29 in Q1 2020.
- Armistice Capital's portfolio value fell 6.7% quarter-over-quarter to $1.62B.
Based on Armistice Capital's 13F filing for Q1 2020, filed 15 May 2020.